

Reetan Patel

From: Helen Neill [REDACTED]

Sent: 02 November 2005 16:38

To: Alana Miller

Subject: Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma

Dear Ms Miller

I have had the opportunity to briefly examine the assessment report on "*Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma*". Due to time constraints, I have focussed on sections 1.1, 3.2.5 and 3.4.

My comments are as follows:

- o Section 3.4.1 (p23) - the cost for an individual Gliadel wafer according to BNF 50 is £650.38
- o Section 3.4.2 (p24) - Temodar is incorrect; it should read *Temodal*. Also consider rephrasing the information on the licensing of temozolomide in children e.g. "TMZ is licensed for use in children 3 years and older" or "TMZ is unlicensed in children under 3 years"

I hope these comments are of use to you.

Helen Neill MPharm, MRPharmS

Staff Editor

British National Formulary
[REDACTED]

Delivered via MessageLabs

20/12/2005